Phase II clinical trial of parenteral hydroxyurea and hyperfractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: Toxicity and efficacy with continuous ribonucleoside reductase inhibition

Head and Neck

Volumn 29, Issue 1, 2007, Pages 18-25

  Beitler, Jonathan J ^a   Smith, Richard V ^a   Owen, Randall P ^a   Silver, Carl E ^a   Mazumdar, Madhu ^b   Wadler, Scott ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cell cycle blockade; Concurrent chemoradiation; Hydroxyurea; Radiosensitizer

Indexed keywords

HYDROXYUREA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPIRATION PNEUMONIA; BLOOD CULTURE; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; DYSPHAGIA; ENZYME INHIBITION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; HYPERFRACTIONATED ACCELERATED EXTERNAL BEAM RADIATION THERAPY; INFECTION; INFUSION PUMP; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; ODYNOPHAGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THRUSH; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; INFUSION PUMPS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 33845956879     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20477     Document Type: Article

References (51)

1. Kashyap AS, Kashyap S. Head and neck cancer. N Engl J Med 2002;346:1416, 1417.
2. Perez CA, Chao KSC, Simpson JR, Schmidt-Ullrich RK. Oropharynx (tonsillar fossa, faucial arch, and base of tongue). In: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, editors. Principles and practice of radiation oncology, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2004. pp 1058-1059.
3. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654.
4. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-955.
5. Forastiere AA. Chemotherapy of head and neck cancer. Ann Oncol 1992;3 (Suppl 3):11-14.
6. Sobrero A, Guglielmi A, Aschele C, Rosso R. Current strategies to reduce cisplatin toxicity. J Chemother 1990;2:3-7.
7. Krakoff IH, Brown NC, Reichard R Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 1968;28:1559-1565.
8. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19(3 Suppl 9):11-19.
9. Xynos FP, Benjamin I, Sapiente R. Adriamycin and hydroxyurea as radiopotentiators in the treatment of squamous cell carcinoma of the cervix implanted in nude mice: a preliminary report. Gynecol Oncol 1980;9:170-176.
10. Sinclair WK. Hydroxyurea: effect on Chinese hamster cells grown in culture. Cancer Res 1967;27:297-308.
11. Sinclair WK. The combined effects of hydroxyurea and x-rays in Chinese hamster cells in vitro. Cancer Res 1968;28:198-206.
12. Piver MS, Howes AE, Suit HD, et al. Effect of hydroxyurea on the radiation response of C3H mouse mammary tumors. Cancer 1972;29:407-412.
13. Phillips RA, Tolmach LJ. Repair of potentially lethal damage in x-irradiated HeLa cells. Radiat Res 1966;29:413-432.
14. Piver MS, Barlow JJ, Vongtama V, Blumenson L. Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study. Am J Obstet Gynecol 1983;147:803-808.
15. Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW III, Shingleton HM, Blessing JA. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 1979;5:317-322.
16. Stefani S, Eells RW, Abbate J. Hydroxyurea and radiotherapy in head and neck cancer. Radiology 1971;101:391-396.
17. Wadler S, Horowitz R, Rao J, Mao X, Schlesinger K, Schwartz EL. Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: effects in wild-type and resistant human colon cancer cells. Cancer Chemother Pharmacol 1996;38:522-528.
18. Rodriguez GI, Kuhn JG, Weiss GR, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 1998;91:1533-1541.
19. Belt RJ, Haas CD, Kennedy J, Taylor S. Studies of hydroxyurea by continuous infusion: toxicity, pharmacokinetics and cell synchronization. Cancer 1980;46:455-462.
20. Newman EM, Carroll M, Akman SA, et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother Pharmacol 1997;39:254-258.
21. Piver MS, Barlow JJ, Vongtama V, Blumenson L. Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. Am J Obstet Gynecol 1977; 129:379-383.
22. Stehman FB, Bundy BN, Thomas G, et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 1993;11:1523-1528.
23. Beitler JJ, Smith RV, Haynes H, et al. A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck. Invest New Drugs 1998;16:161-169.
24. Smith RV, Kotz T, Beitler JJ, Wadler S. Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea: initial results. Arch Otolaryngol Head Neck Surg 2000;126:384-389.
25. Kotz T, Abraham S, Beitler JJ, Wadler S, Smith RV. Pharyngeal transport dysfunction consequent to an organ-sparing protocol. Arch Otolaryngol Head Neck Surg 1999; 125:410-413.
26. Smith RV, Goldman SY, Beitler JJ, Wadler SS. Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:831-836.
27. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-1104.
28. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
29. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:45-52.
30. Wright JA, Chan AK, Choy BK, Hurta RA, McClarty GA, Tagger AY Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. Biochem Cell Biol 1990;68:1364-1371.
31. Hurta RA, Wright JA. Malignant transformation by H-ras results in aberrant regulation of ribonucleotide reductase gene expression by transforming growth factor-β 1. J Cell Biochem 1995;57:543-556.
32. Nielsen BB, Kauppi B, Thelander M, Thelander L, Larsen IK, Eklund H. Crystallization and crystallographic investigations of the small subunit of mouse ribonucleotide reductase. FEBS Lett 1995;373:310-312.
33. Zhou BS, Hsu NY, Pan BC, Doroshow JH, Yen Y. Over-expression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not Ml is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 1995;55: 1328-1333.
34. Cory AH, Sato A, Thompson DP, Cory JG. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone. Oncol Res 1996;8:449-456.
35. Argiris A, Haraf DJ, Kies MS, Vokes EE. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 2003;8:350-360.
36. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-2864.
37. Haraf DJ, Kies M, Rademaker AW, et al. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol 1999;17:638-644.
38. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-1969.
39. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320-326.
40. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
41. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-1348.
42. Nguyen NP, Sallah S, Karlsson U, Antoine JE. Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues. Cancer 2002;94: 1131-1141.
43. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349: 2091-2098.
44. Weber RS, Berkey BA, Forastiere A, et al. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 2003;129: 44-49.
45. Konski A, Scott C, Ang KK, Fu KK. Cost-utility analysis of RTOG 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2001;51:48.
46. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy. a prospective examination. J Clin Oncol 1999;17:1020-1028.
47. Kies MS, Bennett CL, Yokes EE. Locally advanced head and neck cancer. Curr Treat Options Oncol 2001;2:7-13.
48. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head- and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53: 23-28.
49. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004;60:1425-1439.
50. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-799.
51. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.